Arcus Biosciences, Inc. Available-for-sale Securities, Amortized Cost Basis
Arcus Biosciences, Inc. (RCUS) had Available-for-sale Securities, Amortized Cost Basis of $743.46 million as of 2021-09-30, per its 10-Q filed 2021-11-08.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2021-11-08
- 2021-09-30: Available-for-sale Securities, Amortized Cost Basis $743.46M.
- 2021-06-30: Available-for-sale Securities, Amortized Cost Basis $805.15M.
- 2021-03-31: Available-for-sale Securities, Amortized Cost Basis $884.91M.
- 2020-12-31: Available-for-sale Securities, Amortized Cost Basis $735.04M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2021-09-30 | $743.46M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $805.15M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $884.91M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $735.04M 10-Q · filed 2021-11-08 |
| 2020-09-30 | $785.05M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $462.33M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $157.58M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $188.21M 10-K · filed 2021-02-25 |
| 2019-09-30 | $196.93M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $224.29M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $243.11M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $259.83M 10-K · filed 2020-03-05 |
| 2018-09-30 | $265.69M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $277.57M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $290.87M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $175.75M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |